The University of Virginia (UVA) Center for Diabetes Technology and Tandem Diabetes Care have forged a multi-year partnership aimed at advancing the development of fully automated insulin delivery systems, potentially revolutionizing diabetes care worldwide.
Leveraging UVA’s groundbreaking work in diabetes technology and Tandem’s expertise in insulin delivery devices, algorithms, and data management, the collaboration seeks to build upon over a decade of successful research into automated insulin delivery (AID) systems.
A Decade of Progress
The UVA Center has already demonstrated significant success in translating advanced AID algorithms into medical devices used globally. This new phase of collaboration is expected to refine these systems further, enabling transformative improvements in diabetes management.
Dr. Marc Breton, Associate Director for Research at the UVA Center for Diabetes Technology, expressed optimism about the expanded partnership. “After more than 10 years working with the Tandem team, this is an exciting new beginning to our collaboration to serve patients with diabetes. Together, we will expand our research efforts into automated insulin delivery with the goal of once more substantially enhancing care and quality of life for patients around the world,” he said.
Tandem’s Role and Vision
Tandem Diabetes Care, a leader in insulin delivery technology, has a history of advancing closed-loop insulin delivery systems that use real-time glucose monitoring to optimize insulin dosing. This collaboration involves a joint effort by scientists, clinicians, and experts from both organizations to innovate and deliver effective treatments for people living with diabetes.
John Sheridan, President and CEO of Tandem Diabetes Care, highlighted the significance of their longstanding relationship with UVA. “Our past work with UVA, including research related to our automated insulin delivery systems as part of the International Diabetes Closed Loop trials, helped contribute to life-changing products for people living with diabetes. We believe this research collaboration will continue on our joint history of delivering new innovations that can further improve the lives of people living with diabetes,” Sheridan remarked.
Investment in Innovation
As part of the agreement, Tandem Diabetes Care will provide funding, technology, and supplies to support research and potential clinical trials at UVA. The financial backing aims to advance insulin delivery systems, improving their functionality and impact on patient outcomes.
This collaboration underscores a shared commitment to developing more efficient, accessible treatments for diabetes patients worldwide. By combining expertise in medical technology and diabetes care, UVA and Tandem Diabetes Care are poised to make meaningful strides in enhancing the lives of millions managing diabetes.
Related topics:
Study Finds Link Between Radon Exposure and Increased Risk of Gestational Diabetes
Carrots Could Be Key to Better Blood Sugar Control, New Study Suggests
Health Risks of Obesity: Why Weight Loss is Essential for Preventing Chronic Diseases
